SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias shares drew attention after reports of CEO Jensen Huangs admitted affair with a woman alleged to have ties to Chinese intelligence prompted the board to open an independent investigation. Traders debated whether the controversy could threaten Huangs leadership or pose a national-security risk, while many dip buyers argued it does not change Nvidias AI-chip business fundamentals.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A weaker-than-expected Q3 revenue report and sequential sales decline are driving IBRXs sharp selloff, with traders questioning ANKTIVAs commercial uptake and raising concerns about competition, cash burn, and possible dilution. The reaction is divided: some see the results as evidence of weak execution, while others argue the BCG-naive trial success and Israeli approval support longer-term growth.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims is in focus around its quarterly results and its Eli Lilly deal to offer branded obesity drugs through its platform. Traders are split on whether the expanded GLP-1 offering can support growth, with concerns that lower margins could offset the benefit; some also speculate about an earnings leak, without evidence.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Discussion centers on the FDAs pending decision on Capricors deramiocel application for Duchenne muscular dystrophy, with traders focused on HOPE-3 upper-limb data and a letter from trial investigators urging approval. Many expect approval and speculate about a short squeeze, while others stress the binary risk of a rejection or CRL amid lingering FDA concerns.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A sharp rally into The Trade Desks quarterly earnings has traders debating whether optimism about a possible beat and heavy short interest could fuel further gains. Others see the move as a pre-earnings pump and expect a reversal, citing the companys recent weakness and concerns about advertising growth and guidance.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Concern over a congressional report alleging Webull understated its China tiesand related securities lawsuitsdominates discussion of the stocks weakness. Bulls call the claims misleading and view the selloff as a buying opportunity ahead of earnings, while bears worry the allegations could sustain a China-risk discount.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly results beat expectations and management raised its revenue outlook on continued BRIUMVI growth, but shares fell as traders debated a sell-the-news reaction and alleged short-selling pressure. The upcoming Phase 3 readout for subcutaneous BRIUMVI is a major focus for investors looking beyond the earnings report.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs preliminary third-quarter results, which showed strong sales and EBITDA growth, alongside Brad Jacobs bullish conference-call comments, have renewed optimism around the building-products roll-up strategy. Traders celebrated the rebound and speculated about short covering, though some remain cautious after the stocks steep decline.

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Clover Health Investments Corp

Clover Health is drawing attention after traders reacted to strong Q3 results, improved full-year guidance, and continued profitability and membership growth. Bulls welcomed the results and renewed move above $5, while others questioned the muted reaction and the lack of concrete Counterpart Health software-revenue details.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Heavy selling is centered on concerns about Arrowheads commercial execution, with traders criticizing Redemplos sales and the companys losses while comparing its launch with Ioniss Tryngolza. Some see weak competitor sales as an opening for Redemplo, but others question whether uptake and revenue justify the companys valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
